Curated News
By: NewsRamp Editorial Staff
June 09, 2026
Aptevo and Niowave Join Forces in Radiopharmaceutical Cancer Fight
TLDR
- Aptevo and Niowave's radiopharmaceutical collaboration targets a $17B market with a precision approach that big pharma struggles to replicate.
- Radiopharmaceutical therapy uses a targeting molecule to find cancer cells and a radioactive isotope to destroy them, sparing healthy tissue.
- This targeted therapy aims to treat metastatic cancers with fewer side effects, improving quality of life for patients with difficult-to-treat tumors.
- Aptevo and Niowave combine tumor targeting with isotope supply to overcome key barriers in the radiopharmaceutical field.
Impact - Why it Matters
This collaboration matters because it addresses two critical bottlenecks in radiopharmaceutical therapy: precise tumor targeting and reliable isotope supply. By combining Aptevo's multispecific antibody platforms with Niowave's manufacturing capabilities, the partnership could accelerate the development of safer, more effective cancer treatments that minimize collateral damage. For patients with metastatic cancers, this means potential access to therapies that directly destroy tumors without the severe side effects of traditional approaches. The $17 billion investment in the field underscores the high expectations, and this alliance could help unlock the full potential of radiopharmaceuticals, offering hope for those with high unmet medical needs.
Summary
Radiopharmaceutical therapy (RPT) is emerging as a groundbreaking approach to treating metastatic cancers, aiming to directly target cancer cells while sparing healthy tissue. This method has attracted over $17 billion in investments, according to Aptevo Therapeutics Inc. (NASDAQ: APVO). To advance this field, better tumor targeting and reliable isotope access are crucial. Aptevo, a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, has teamed up with Niowave Inc., a leader in radioisotope production and supply, in a 50/50 strategic collaboration to develop up to three radiopharmaceutical oncology programs. Niowave also made an equity investment in Aptevo, initially representing a 7.9% ownership stake, with potential to increase to 19.99%. The partnership leverages Aptevo's multispecific platforms and Niowave's manufacturing capabilities to create targeted cancer treatments.
The collaboration marks Aptevo's entry into radiopharmaceuticals, building on its existing phase 1b clinical trial of mipletamig for acute myeloid leukemia (AML). Aptevo's ADAPTIR™ and ADAPTIR-FLEX™ platforms are modular protein technologies designed to create precise antibodies that engage the immune system. For Niowave, this is its first foray into therapeutic development, extending beyond isotope supply. The initial program targets Nectin-4, a clinically validated cancer target expressed on solid tumors, using actinium-225 and other radioisotopes provided by Niowave. The companies are ready to initiate the first stage, with potential catalysts ahead.
The timing is strategic, as radiopharmaceutical therapy gains traction among Big Pharma, which has invested heavily in emerging companies. Limited access to isotopes and manufacturing infrastructure has constrained development, but Niowave's established supply relationships address this bottleneck. By combining Aptevo's targeting with Niowave's isotopes, the duo aims to overcome these limitations and advance treatments for difficult-to-treat cancers. To learn more about Aptevo, click here.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Aptevo and Niowave Join Forces in Radiopharmaceutical Cancer Fight
